BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
43 hedge funds and large institutions have $17.7M invested in BRAINSTORM CELL THERAPUTC in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 15 closing their positions.
5% more capital invested
Capital invested by funds: $16.9M → $17.7M (+$838K)
0.13% less ownership
Funds ownership: 0.94% → 0.82% (-0.13%)
17% less funds holding
Funds holding: 52 → 43 (-9)
23% less call options, than puts
Call options by funds: $2.96M | Put options by funds: $3.87M
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCG
Weaver Consulting Group
Huntington Beach,
California
|
+$341K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$121K |
| 3 |
AHB
Abner Herrman & Brock
Jersey City,
New Jersey
|
+$91.8K |
| 4 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$33.1K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$17.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$829K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$568K |
| 3 |
E
Ergoteles
New York
|
-$405K |
| 4 |
PVI
Pura Vida Investments
New York
|
-$353K |
| 5 |
HF
HRT Financial
New York
|
-$268K |
BCLI Hedge Fund Activity: Q4 2021 in Review
43 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2021, worth a combined $17.7M — up 5% from $16.9M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of BCLI and 7 opened new positions — a net loss of 8 holders — while 12 trimmed existing stakes and 8 added.
The largest buyer was Weaver Consulting Group, adding an estimated $341K. The largest seller was JP Morgan Chase, cutting an estimated $829K.
- 43 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2021, down from 52 in Q3 2021.
- Funds reported $17.7M of BRAINSTORM CELL THERAPUTC stock for Q4 2021, up 5% quarter-over-quarter.
- 7 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2021 and 15 closed out, a net change of -8 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2021 was Weaver Consulting Group, an estimated $341K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q4 2021 was JP Morgan Chase, an estimated $829K sold.
Based on aggregated 13F filings for Q4 2021.